GlassScriptPhysician profile
Vitaly Geyfman
NPI 1558339143
$14,793.62
in general payments reported to CMS, 2019-2025
27 companies · $1,927 in 2025
The $1,927 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,832 · 2020: $224 · 2021: $819 · 2022: $3,497 · 2023: $3,284 · 2024: $1,212 · 2025: $1,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,786 · Travel and Lodging: $1,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,786.17 |
| Travel and Lodging | $1,636.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,019.85 | 2021-2025 | Diamondtemp Bidirectional Ablation Catheter, Onyx Frontier, Micra |
| Medtronic Vascular, INC. | $3,730.72 | 2019 | |
| Boston Scientific Corporation | $1,785.89 | 2019-2025 | Rhythmia Mapping System, Lux-Dx Insertable Cardiac Monitor, Accolade Sr |
| Novartis Pharmaceuticals Corporation | $1,010.21 | 2021-2025 | |
| Abbott Laboratories | $967.95 | 2019-2025 | Aveir, Confirm Rx, Jot Dx |
| Pfizer INC. | $416.79 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $397.63 | 2020-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $369.57 | 2020-2024 | Xarelto |
| Shockwave Medical, INC | $138.31 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.35 | 2023-2025 | Lifevest |
| Edwards Lifesciences Corporation | $114.28 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.45 | 2024 | Jardiance |
| Novo Nordisk INC | $90.91 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Abiomed | $88.16 | 2022-2025 | Impella |
| Baxter Healthcare | $68.20 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $63.86 | 2023-2024 | Farxiga, Brilinta |
| Bayer Healthcare Pharmaceuticals INC. | $60.87 | 2025 | |
| Merck Sharp & Dohme LLC | $54.41 | 2023-2025 | Verquvo |
| Scpharmaceuticals INC. | $37.18 | 2025 | |
| Philips North America LLC | $35.83 | 2024 | (Ck7) Extended Holter |
| W. L. Gore & Associates, INC. | $21.19 | 2022 | |
| Bridgebio Pharma, INC. | $18.78 | 2025 | Attruby |
| Terumo Medical Corporation | $15.71 | 2021 | |
| Esperion Therapeutics, INC. | $15.29 | 2021 | |
| Lantheus Medical Imaging, INC. | $13.14 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $12.91 | 2024 | Uptravi, Opsumit |
| Kiniksa Pharmaceuticals, LTD. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vitaly Geyfman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.